Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 85

1.

Aberrant Expression of RAD52, Its Prognostic Impact in Rectal Cancer and Association with Poor Survival of Patients.

Ho V, Chung L, Singh A, Lea V, Abubakar A, Lim SH, Chua W, Ng W, Lee M, Roberts TL, de Souza P, Lee CS.

Int J Mol Sci. 2020 Mar 4;21(5). pii: E1768. doi: 10.3390/ijms21051768.

2.

Association Between Microsatellite Instability Status and Peri-Operative Release of Circulating Tumour Cells in Colorectal Cancer.

Toh JWT, Lim SH, MacKenzie S, de Souza P, Bokey L, Chapuis P, Spring KJ.

Cells. 2020 Feb 12;9(2). pii: E425. doi: 10.3390/cells9020425.

3.

Safety, Pharmacokinetics, and Clinical Activity of Adavosertib in Combination with Chemotherapy in Asian Patients with Advanced Solid Tumors: Phase Ib Study.

Kato H, de Souza P, Kim SW, Lickliter JD, Naito Y, Park K, Kumar S, Mugundu GM, Bang YJ.

Target Oncol. 2020 Feb;15(1):75-84. doi: 10.1007/s11523-020-00701-5.

4.

CPF impedes cell cycle re-entry of quiescent lung cancer cells through transcriptional suppression of FACT and c-MYC.

Bi L, Xie C, Jiao L, Jin S, Hnit SST, Mu Y, Wang Y, Wang Q, Ge G, Wang Y, Zhao X, Shi X, Kang Y, De Souza P, Liu T, Zhou J, Xu L, Dong Q.

J Cell Mol Med. 2020 Feb;24(3):2229-2239. doi: 10.1111/jcmm.14897. Epub 2020 Jan 20.

5.

Transcriptional regulation of G2/M regulatory proteins and perturbation of G2/M Cell cycle transition by a traditional Chinese medicine recipe.

Hnit SST, Yao M, Xie C, Ge G, Bi L, Jin S, Jiao L, Xu L, Long L, Nie H, Jin Y, Rogers L, Suchowerska N, Wong M, Liu T, De Souza P, Li Z, Dong Q.

J Ethnopharmacol. 2019 Dec 29;251:112526. doi: 10.1016/j.jep.2019.112526. [Epub ahead of print]

PMID:
31893534
6.

Phase I dose-escalation study to determine the safety, tolerability, preliminary efficacy and pharmacokinetics of an intratumoral injection of tigilanol tiglate (EBC-46).

Panizza BJ, de Souza P, Cooper A, Roohullah A, Karapetis CS, Lickliter JD.

EBioMedicine. 2019 Dec;50:433-441. doi: 10.1016/j.ebiom.2019.11.037. Epub 2019 Dec 3.

7.

Pembrolizumab for anaplastic thyroid cancer: a case study.

Aghajani MJ, Cooper A, McGuire H, Jeffries T, Saab J, Ismail K, de Souza P, Bray V, Fazekas de St Groth B, Niles N, Roberts TL.

Cancer Immunol Immunother. 2019 Dec;68(12):1921-1934. doi: 10.1007/s00262-019-02416-7. Epub 2019 Oct 22.

PMID:
31637475
8.

Health-Related Quality of Life during Chemoradiation in Locally Advanced Rectal Cancer: Impacts and Ethnic Disparities.

Lim SH, Ip E, Ng W, Chua W, Asghari R, Roohullah A, Descallar J, Henderson C, Spring K, de Souza P, King MT.

Cancers (Basel). 2019 Aug 28;11(9). pii: E1263. doi: 10.3390/cancers11091263.

9.

The impact of neutrophil-lymphocyte ratio on risk reclassification of patients with advanced renal cell cancer to guide risk-directed therapy.

Tjokrowidjaja A, Goldstein D, Hudson HM, Lord SJ, Gebski V, Clarke S, de Souza P, Motzer RJ, Lee CK.

Acta Oncol. 2020 Jan;59(1):20-27. doi: 10.1080/0284186X.2019.1656342. Epub 2019 Aug 29.

PMID:
31462137
10.

Plasma next generation sequencing and droplet digital PCR-based detection of epidermal growth factor receptor (EGFR) mutations in patients with advanced lung cancer treated with subsequent-line osimertinib.

Ding PN, Becker T, Bray V, Chua W, Ma Y, Xu B, Lynch D, de Souza P, Roberts T.

Thorac Cancer. 2019 Oct;10(10):1879-1884. doi: 10.1111/1759-7714.13154. Epub 2019 Aug 15.

11.

Detection of AR-V7 in Liquid Biopsies of Castrate Resistant Prostate Cancer Patients: A Comparison of AR-V7 Analysis in Circulating Tumor Cells, Circulating Tumor RNA and Exosomes.

Nimir M, Ma Y, Jeffreys SA, Opperman T, Young F, Khan T, Ding P, Chua W, Balakrishnar B, Cooper A, De Souza P, Becker TM.

Cells. 2019 Jul 8;8(7). pii: E688. doi: 10.3390/cells8070688.

12.

Patterns of Presentation and Treatment Outcomes of Non-clear-cell Renal Cell Carcinoma and Sarcomatoid Renal Cell Carcinoma Patients in 2 Tertiary Referral Centers in Sydney, Australia.

Naher S, Padinharakam S, Balakrishnar B, Chua W, Descallar J, Adams D, de Souza P, Harrison M, Lim S.

Clin Genitourin Cancer. 2019 Jun;17(3):e565-e569. doi: 10.1016/j.clgc.2019.02.006. Epub 2019 Feb 27.

PMID:
30935815
13.

First-in-human phase I study of infusional and bolus schedules of Deflexifol, a novel 5-fluorouracil and leucovorin formulation, after failure of standard treatment.

Clingan PR, Ackland SP, Brungs D, de Souza P, Aghmesheh M, Garg MB, Ranson RD, Parker S, Jokela R, Ranson M.

Asia Pac J Clin Oncol. 2019 Jun;15(3):151-157. doi: 10.1111/ajco.13144. Epub 2019 Mar 6.

PMID:
30843362
14.

Individualising difference, negotiating culture: Intersections of culture and care.

Broom A, Kirby E, Kokanovi─ç R, Woodland L, Wyld D, de Souza P, Koh ES, Lwin Z.

Health (London). 2019 Feb 13:1363459319829192. doi: 10.1177/1363459319829192. [Epub ahead of print]

PMID:
30755040
15.

Immunomagnetic isolation of circulating melanoma cells and detection of PD-L1 status.

Po JW, Ma Y, Balakrishna B, Brungs D, Azimi F, de Souza P, Becker TM.

PLoS One. 2019 Feb 8;14(2):e0211866. doi: 10.1371/journal.pone.0211866. eCollection 2019.

16.

The histone chaperone complex FACT promotes proliferative switch of G0 cancer cells.

Bi L, Xie C, Yao M, Thae Hnit SS, Vignarajan S, Wang Y, Wang Q, Xi Z, Xu H, Li Z, de Souza P, Tee A, Wong M, Liu T, Zhao X, Zhou J, Xu L, Dong Q.

Int J Cancer. 2019 Jul 1;145(1):164-178. doi: 10.1002/ijc.32065. Epub 2018 Dec 28.

PMID:
30548853
17.

Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint.

Basch EM, Scholz M, de Bono JS, Vogelzang N, de Souza P, Marx G, Vaishampayan U, George S, Schwarz JK, Antonarakis ES, O'Sullivan JM, Kalebasty AR, Chi KN, Dreicer R, Hutson TE, Dueck AC, Bennett AV, Dayan E, Mangeshkar M, Holland J, Weitzman AL, Scher HI.

Eur Urol. 2019 Jun;75(6):929-937. doi: 10.1016/j.eururo.2018.11.033. Epub 2018 Dec 4.

18.

Overexpression of the MRE11-RAD50-NBS1 (MRN) complex in rectal cancer correlates with poor response to neoadjuvant radiotherapy and prognosis.

Ho V, Chung L, Singh A, Lea V, Abubakar A, Lim SH, Ng W, Lee M, de Souza P, Shin JS, Lee CS.

BMC Cancer. 2018 Sep 3;18(1):869. doi: 10.1186/s12885-018-4776-9.

19.

Improved ovarian cancer EMT-CTC isolation by immunomagnetic targeting of epithelial EpCAM and mesenchymal N-cadherin.

Po JW, Roohullah A, Lynch D, DeFazio A, Harrison M, Harnett PR, Kennedy C, de Souza P, Becker TM.

J Circ Biomark. 2018 Jun 24;7:1849454418782617. doi: 10.1177/1849454418782617. eCollection 2018 Jan-Dec.

20.

Safety and Efficacy of Oxaliplatin Doublet Adjuvant Chemotherapy in Elderly Patients With Stage III Colon Cancer.

Brungs D, Aghmesheh M, de Souza P, Carolan M, Clingan P, Rose J, Ranson M.

Clin Colorectal Cancer. 2018 Sep;17(3):e549-e555. doi: 10.1016/j.clcc.2018.05.004. Epub 2018 May 31.

PMID:
29861156

Supplemental Content

Loading ...
Support Center